IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Detailed price information for Chemomab Therapeutics Ltd ADR (CMMB-Q) from The Globe and Mail including charting and trades.

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

For the quarter ended September 30, 2025, the Company reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, compared to a net loss applicable to common ...

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Received FDA Fast Track designation for stenoparib in advanced ovarian cancerReported landmark median overall survival now exceeding 25 ...
eLife

Elevated DNA damage without signs of aging in the short-sleeping Mexican cavefish

Cavefish exhibit resilience to chronic sleep loss and tolerate elevated DNA damage and reduced DNA repair responses without compromising healthspan or longevity.